Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation, which is a major contributor to Atopic...Find More
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did not cease developing new treatments this year. The US Food and Drug Administration maintained a rapid rate of new drug approvals this year, all while managing the urgent examination of COVID-19 tests, treatments, and vaccines un...Find More
Pharmaceutical companies play a vital part in our lives and in helping us to live healthier lives. The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, ...Find More
Insulin is a hormone secreted by the beta cells of the islets of langerhans in the pancreas. The hormone is responsible for the maintenance of normal blood glucose levels by facilitating cellular glucose uptake and regulating carbohydrate, protein, and lipid metabolism. Inappropriate functioning of insulin due to d...Find More
Ocugen-Bharat Biotech’s Covaxin Shows Efficacy Against B.1.617 Variant With the COVID-19 cases exponentially increasing, there is a worrisome climate all over the world. Physicians, doctors, researchers, the whole healthcare and pharmaceutical industry are at their toes fighting the second wave of the coronaviru...Find More
Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading patient advocacy group for an upfront payment of USD 5.5 million. TSHA-120 is an intrathecally dosed AAV9 gene therapy designed to tre...Find More
Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to younger patients, the company is reinforcing its pipeline with a pair of early-stage programs from Sanofi. In exchange for the global righ...Find More
Pfizer succeeds COVID-19 vaccine safety milestone Pfizer prepares to file its COVID-19 vaccine for emergency use authorization (EUA) after succeeding a key safety breakthrough. Pfizer now has the median two-month follow-up data needed for securing EUA from the FDA, moving a step closer for bringing its vaccine t...Find More
Bristol Myers' Experimental Psoriasis drug succeeds in late-stage study defeats rival Amgen's Otezla Bristol Myers' experimental psoriasis drug, deucravacitinib has outmarched Amgen's Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial in patients with moderate to severe plaque psoriasis. Deucravaci...Find More
New strategy, new outlook: Sanofi takes another step, gains full control over the Principia’s MS treatment Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected t...Find More
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.